Cagrilintide Protocol Guide: Amylin-Based Appetite Regulation and GLP-1 Stack Optimization
Cagrilintide is a long-acting amylin analogue that mimics the satiety hormone naturally co-secreted with insulin. Used either as monotherapy or combined with a GLP-1 agonist (the "CagriSema" combination), it slows gastric emptying, reduces food intake, and reactivates the satiety sensor — making it especially useful for breaking weight-loss plateaus.
Protocol Quick Reference
Who Is This Protocol For?
Cagrilintide is well-suited for individuals who have plateaued on GLP-1 monotherapy, those seeking enhanced satiety alongside metabolic peptides, and patients pursuing the most effective combination weight-loss strategies.
- Plateaued GLP-1 users who need an additional satiety mechanism to resume progress
- Patients targeting comprehensive weight loss via combination therapy with Semaglutide, Tirzepatide, or Retatrutide
- Adults with strong food cravings or volumetric eating patterns that GLP-1 alone has not fully resolved
- Those tolerating GLP-1 well and ready to amplify results with a complementary mechanism
Cagrilintide is not appropriate for those with severe gastroparesis, hypoglycemia unawareness, pregnancy, or known hypersensitivity. Combination protocols require additional physician oversight, particularly during titration.
How Cagrilintide Works: Mechanism of Action
Cagrilintide is a synthetic amylin receptor agonist designed to mimic endogenous amylin, a hormone co-secreted with insulin from pancreatic β-cells. Its modified structure provides a half-life supporting once-weekly subcutaneous dosing.
Primary Mechanisms
- Slowed gastric emptying: Prolongs satiety after meals and blunts postprandial glucose excursions.
- Reduced food intake: Acts on amylin receptors in the area postrema and hypothalamus to suppress hunger and reduce meal size.
- Central satiety regulation: Engages amylin pathways distinct from GLP-1, providing complementary appetite control when combined.
- Synergy with GLP-1 agonists: The CagriSema combination (Cagrilintide + Semaglutide) showed roughly 15-17% body weight loss in Phase 2, exceeding either monotherapy.
- Plateau reactivation: Low-dose Cagrilintide on offset days can "reactivate the satiety sensor" in individuals stalled on GLP-1 therapy.
Detailed Protocol
Cagrilintide is dosed differently depending on whether it is used as monotherapy or stacked with a GLP-1 receptor agonist.
Stand-Alone Protocol
| Phase | Weekly Dose | Duration |
|---|---|---|
| Starting | 0.25 mg subcutaneous | 4 weeks |
| Step Up | 0.5 mg subcutaneous | 4+ weeks |
| Maintenance | 1 – 2 mg subcutaneous | Ongoing |
| Maximum | 2 mg / week | Do not exceed |
Combo Protocol (with GLP-1 Agonist)
Pair with Semaglutide, Tirzepatide, or Retatrutide. Cagrilintide is administered on a different day than the GLP-1 to spread effects across the week and aid plateau breaks.
- Starting: 250 mcg subcutaneous, once or twice per week (offset from GLP-1 day)
- Maximum: 2 mg per week
- Goal: Reactivate satiety, accelerate stalled fat loss, or sustain results during GLP-1 dose holds
Reconstitution Reference (BAC water)
| Vial | BAC Water | Dosage | Insulin Units | Total Doses |
|---|---|---|---|---|
| 8 mg | 3 mL | 0.25 mg | 10 | 32* |
| 8 mg | 3 mL | 0.5 mg | 20 | 16* |
| 8 mg | 3 mL | 1 mg | 40 | 8* |
| 8 mg | 3 mL | 1.5 mg | 55 | 5 |
| 8 mg | 3 mL | 2 mg | 75 | 4 |
*Concentrations yielding more than six doses per vial may compromise BAC water stability outside clinical settings.
Constipation Relief: Adding 200 mg magnesium glycinate at night is commonly recommended to mitigate constipation, particularly during combo protocols.
What to Expect: Results Timeline
Week 1-4: Onset Phase
- - Reduced meal volume and earlier satiety
- - Mild nausea is possible at start; usually transient
- - Modest weight movement begins; stronger when stacked
Week 5-16: Active Phase
- - Plateau-breaking effect commonly observed in stalled GLP-1 users
- - Improved diet adherence due to reduced cravings
- - Combo protocols (CagriSema-style) typically deliver the strongest weight loss
Month 4-12: Maintenance Phase
- - Used to sustain weight loss during GLP-1 dose holds
- - Long-term satiety regulation supports weight maintenance
- - Physician evaluates ongoing combo strategy
Potential Side Effects
Common (typically transient)
- Nausea, particularly during initiation or dose increases
- Constipation
- Reduced appetite (intended; sometimes excessive)
- Mild fatigue early in the protocol
Uncommon (report to your physician)
- Persistent vomiting or dehydration
- Hypoglycemia (especially when stacked with insulin or GLP-1 + insulin)
- Significant muscle loss without resistance training and adequate protein
Safety Note: When stacked with a GLP-1 agonist, dose escalation should be slow and lab-guided. Maintain ≥1.6 g/kg protein and resistance train 2-3x/week to preserve lean mass.
Stacking Options
Cagrilintide + Semaglutide (CagriSema-style)
The most studied combination: GLP-1 + amylin agonism. Typically delivers stronger weight-loss effects than Semaglutide alone, with manageable side-effect profile when titrated carefully.
Cagrilintide + Tirzepatide
Used for plateau-resistant cases on Tirzepatide. The amylin pathway adds a complementary satiety mechanism distinct from GIP/GLP-1.
Cagrilintide + Retatrutide (Advanced)
An aggressive combination for severe plateaus. Reserved for tightly monitored cases with comprehensive labs and lifestyle support.
Why Run Your Cagrilintide Protocol with Hatter Labs
Combination metabolic protocols benefit most from physician oversight, lab tracking, and protein/training guidance. Hatter Labs structures the entire CagriSema-style stack as a single supervised plan.
Start Your Cagrilintide ProtocolMedical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Cagrilintide is a research peptide; not all uses are FDA-approved. Individual results vary. Always consult a qualified healthcare provider before starting any peptide therapy. Hatter Labs protocols are supervised by licensed physicians who evaluate health history, contraindications, and treatment goals before prescribing.